Job Growth Slows in June, Yellen's China Talks, Twitter Threatens Meta 7/7/23
Squawk on the Street
00:00
The FDA Squawks at the Approval of the Sal Timers Drug for Biogen
The FDA squawked at a great job covering the approval of the Sal timers drug LeCambie for Biogen. It could be a little clunky for a while before it really becomes much more mainstream, especially as a treatment for the very, very large total addressable market that is all farmers. We'll watch to see what kind of policy moves they make in terms of coverage. But what's going to feed the argument once again that we are in some kind of golden age regarding Alzheimer's, certainly cancer vaccines and mRNA technology. I mean, good time to be around.
Play episode from 37:42
Transcript
